Regeneron Pharmaceuticals · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← REGN

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q3	2026-09-30	5.12	+36.3%	—	2.05	1.95	38.1%	1.78	18.45	0.40	0.10
FY2026 Q2	2026-06-30	4.29	+16.7%	—	1.29	1.30	30.2%	0.81	12.23	1.17	0.10
FY2026 Q1	2026-03-31	3.61	+19.0%	—	0.64	0.73	20.2%	1.08	6.75	0.79	0.10
FY2025 Q4	2025-12-31	3.88	+2.5%	—	0.88	0.84	21.7%	1.17	7.78	0.67	0.09
FY2025 Q3	2025-09-30	3.75	+0.9%	—	1.03	1.46	38.9%	1.62	13.62	0.66	0.09
FY2025 Q2	2025-06-30	3.68	+3.6%	—	1.08	1.39	37.9%	1.14	12.81	1.06	0.09
FY2025 Q1	2025-03-31	3.03	−3.7%	—	0.59	0.81	26.7%	1.05	7.27	1.04	0.09
FY2024 Q4	2024-12-31	3.79	+10.3%	—	0.99	0.92	24.2%	1.26	8.12	0.97	0.00
FY2024 Q3	2024-09-30	3.72	+10.6%	—	1.18	1.34	36.0%	1.29	11.54	0.74	0.00
FY2024 Q2	2024-06-30	3.55	+12.3%	—	1.07	1.43	40.4%	0.35	12.41	0.60	0.00
FY2024 Q1	2024-03-31	3.15	−0.5%	—	0.75	0.72	23.0%	1.51	6.27	0.29	0.00
FY2023 Q4	2023-12-31	3.43	+0.6%	—	0.97	1.16	33.8%	1.09	10.21	0.29	—
FY2023 Q3	2023-09-30	3.36	—	—	1.11	1.01	30.0%	1.11	8.89	0.55	—
FY2023 Q2	2023-06-30	3.16	—	—	1.02	0.97	30.7%	1.02	8.50	0.69	—
FY2023 Q1	2023-03-31	3.16	—	—	0.95	0.82	25.9%	1.37	7.17	0.71	—
FY2022 Q4	2022-12-31	3.41	—	—	1.15	1.20	35.1%	1.72	10.48	0.43	—

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.